NO981374L - Dendrittcellestimulerende faktor - Google Patents

Dendrittcellestimulerende faktor

Info

Publication number
NO981374L
NO981374L NO981374A NO981374A NO981374L NO 981374 L NO981374 L NO 981374L NO 981374 A NO981374 A NO 981374A NO 981374 A NO981374 A NO 981374A NO 981374 L NO981374 L NO 981374L
Authority
NO
Norway
Prior art keywords
cells
stimulating factor
dendritic cell
cell stimulating
vivo
Prior art date
Application number
NO981374A
Other languages
English (en)
Norwegian (no)
Other versions
NO981374D0 (no
Inventor
Kenneth Brasel
Stewart D Lyman
Eugene Maraskovsky
Hilary R Mckenna
David H Lynch
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO981374D0 publication Critical patent/NO981374D0/no
Publication of NO981374L publication Critical patent/NO981374L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NO981374A 1995-10-04 1998-03-26 Dendrittcellestimulerende faktor NO981374L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53914295A 1995-10-04 1995-10-04
PCT/US1996/015990 WO1997012633A1 (en) 1995-10-04 1996-10-03 Dendritic cell stimulatory factor

Publications (2)

Publication Number Publication Date
NO981374D0 NO981374D0 (no) 1998-03-26
NO981374L true NO981374L (no) 1998-06-03

Family

ID=24149974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981374A NO981374L (no) 1995-10-04 1998-03-26 Dendrittcellestimulerende faktor

Country Status (23)

Country Link
EP (1) EP0871487B1 (de)
JP (1) JP3631496B2 (de)
KR (2) KR100514957B1 (de)
CN (1) CN1172718C (de)
AT (1) ATE432085T1 (de)
AU (1) AU697539B2 (de)
BR (1) BR9610802A (de)
CA (1) CA2232865A1 (de)
CZ (1) CZ97798A3 (de)
DE (1) DE69637942D1 (de)
EA (1) EA199800272A1 (de)
EE (1) EE9800105A (de)
ES (1) ES2323818T3 (de)
IS (1) IS4703A (de)
LV (1) LV12085B (de)
NO (1) NO981374L (de)
NZ (1) NZ321039A (de)
PL (1) PL187329B1 (de)
RO (1) RO120579B1 (de)
SI (1) SI9620116A (de)
SK (1) SK40898A3 (de)
TR (1) TR199800607T1 (de)
WO (1) WO1997012633A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
NZ333607A (en) * 1996-07-10 2000-08-25 Immunex Corp Method of stimulating the immune system by transfecting dendritic cells
AUPO388396A0 (en) * 1996-11-27 1996-12-19 Ludwig Institute For Cancer Research Cellular adjuvant
WO1998057655A1 (en) * 1997-06-17 1998-12-23 Immunex Corporation A method of enhancing antigen-specific peripheral immune tolerance
FR2775692B1 (fr) * 1998-03-03 2000-06-16 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2782524B1 (fr) * 1998-08-21 2002-07-19 Roussy Inst Gustave Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US6291661B1 (en) 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
AU5741699A (en) 1998-08-27 2000-03-21 Universitatsklinikum Freiburg Low-molecular fragments of hyaluronic acid for the preparation of vaccines
GB9827604D0 (en) * 1998-12-15 1999-02-10 Lorantis Ltd Methods of immunosuppression
WO2001009303A2 (en) * 1999-07-30 2001-02-08 Vical Inc. Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
WO2001032204A2 (en) * 1999-11-03 2001-05-10 Powderject Vaccines, Inc. Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
AU2001239873A1 (en) * 2000-02-24 2001-09-03 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
EP1276501B9 (de) * 2000-04-25 2007-01-24 Immunex Corporation Behandlung von tumoren mit photodynamischer therapie
AU2002232447A1 (en) * 2000-11-02 2002-05-15 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
AU2002225927A1 (en) * 2000-11-17 2002-05-27 Immunex Corporation Chemoattractant recruitment of dendritic cells for enhancement of immunization
CN1636229B (zh) * 2001-09-06 2012-12-19 西北生物治疗药物公司 引发单核树突细胞和t细胞th-1应答的组合物和方法
KR100490308B1 (ko) * 2002-02-25 2005-05-17 크레아젠 주식회사 면역 치료용 성숙화된 수지상 세포 백신의 제조방법
AU2003224810B2 (en) * 2002-03-26 2006-08-31 Immunex Corporation Methods of using Flt3-ligand in immunization protocols
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
KR100614220B1 (ko) * 2004-11-08 2006-08-21 고려대학교 산학협력단 Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
DE102005016234B4 (de) * 2005-04-08 2008-05-15 Tgc Biomics Gmbh Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen
KR100818215B1 (ko) 2006-10-11 2008-04-01 재단법인서울대학교산학협력재단 Ｃｄ３４양성 줄기세포로부터 ｔ 임파구 전구체를 제조하는 방법
KR101264811B1 (ko) 2011-05-20 2013-05-15 충남대학교산학협력단 마이코박테리움 압세수스의 ＭＡＢ０９８１ｃ 단백질을 이용한 수지상 세포의 성숙방법
WO2018013820A1 (en) * 2016-07-13 2018-01-18 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
JP7642542B2 (ja) 2018-12-18 2025-03-10 ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド Ｆｌｔ３アゴニスト抗体及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US826250A (en) 1905-12-20 1906-07-17 Albert Huck Switch for toy railways.
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
EP0275598B1 (de) 1986-12-16 1998-01-07 Gist-Brocades N.V. Molekulare Klonierung und Expression von menschlichem IL-3
OA09736A (en) 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
EP0391892A4 (en) 1987-10-30 1990-11-28 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
SG59931A1 (en) 1989-10-16 1999-02-22 Amgen Inc Stem cell factor
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
CA2122141C (en) 1991-10-23 2007-07-17 Shelly Heimfeld Methods for selectively expanding stem cells
NZ314644A (en) * 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells

Also Published As

Publication number Publication date
IS4703A (is) 1998-03-26
PL325964A1 (en) 1998-08-17
EE9800105A (et) 1998-10-15
SK40898A3 (en) 1999-04-13
PL187329B1 (pl) 2004-06-30
ES2323818T3 (es) 2009-07-24
EA199800272A1 (ru) 1998-10-29
KR20040079421A (ko) 2004-09-14
KR19990063818A (ko) 1999-07-26
CA2232865A1 (en) 1997-04-10
JPH11513389A (ja) 1999-11-16
CN1172718C (zh) 2004-10-27
EP0871487A1 (de) 1998-10-21
EP0871487A4 (de) 2004-09-01
DE69637942D1 (de) 2009-07-09
CN1229359A (zh) 1999-09-22
AU697539B2 (en) 1998-10-08
NO981374D0 (no) 1998-03-26
JP3631496B2 (ja) 2005-03-23
TR199800607T1 (xx) 1998-06-22
BR9610802A (pt) 1999-07-13
NZ321039A (en) 2001-03-30
SI9620116A (sl) 1999-08-31
KR100514957B1 (ko) 2005-11-25
KR100676792B1 (ko) 2007-02-02
EP0871487B1 (de) 2009-05-27
RO120579B1 (ro) 2006-04-28
LV12085B (en) 1998-09-20
ATE432085T1 (de) 2009-06-15
AU7392296A (en) 1997-04-28
LV12085A (lv) 1998-07-20
WO1997012633A1 (en) 1997-04-10
CZ97798A3 (cs) 1999-02-17

Similar Documents

Publication Publication Date Title
NO981374L (no) Dendrittcellestimulerende faktor
GR3036951T3 (en) Cells with multiple altered epitopes on a surface antigen for use in transplantation
Baldwin et al. Immunology of spontaneously arising rat mammary adenocarcinomas
DE69329344D1 (de) Spezifische modulationen des immunsystems
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
DK0871414T3 (da) Fremgangsmåder til fremstilling af væv til implantering
GR3020240T3 (en) Generation of xenogeneic antibodies
DK0977874T3 (da) Svækket salmonella-stamme anvendt som bæremedium til oral immunisering
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
JPS5533474A (en) Vaccine and its manufacture
Kedar et al. In vitro induction of cell-mediated immunity to murine leukemia cells. I. Optimization of tissue culture conditions for the generation of cytotoxic lymphocytes
DK1021196T3 (da) Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
Prager et al. Immunological stimulation with modified lymphoma cells in a minimally responsive tumor-host system
ATE412763T1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität
AR015237A1 (es) Una composicion de membranas celulares tumorales modificadas con hapteno, metodo para obtenerlas y su uso.
AU5573196A (en) A pluripotent vaccine against enveloped viruses
DE60130634D1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
Froese et al. Brief communication: Neuraminidase-induced enhancement of tumor growth in mice
Bonavida The SJL/J spontaneous reticulum cell sarcoma: new insights in the fields of neoantigens, host-tumor interactions, and regulation of tumor growth
AU1256495A (en) Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
SE8205247D0 (sv) Fiskvacciner
Yefenof et al. Nonimmunogenic radiation-induced lymphoma: Immunity induction by a somatic cell hybrid
MX2026001604A (es) Proteinas modificadas
Neri et al. Influence of neuraminidase and mitomycin C on the immunogenicity of Novikoff tumor cells